⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16850631 | 0.73 | — | — | |
| SCHEMBL10403535 | 0.71 | — | — | |
| SCHEMBL17832467 | 0.71 | — | — | |
| SCHEMBL1270987 | 0.71 | — | — | |
| SCHEMBL307413 | 0.71 | — | — | |
| SCHEMBL12517978 | 0.70 | — | — | |
| SCHEMBL4445528 | 0.67 | — | — | |
| SCHEMBL343264 | 0.67 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL10564448 | 0.67 | — | — | |
| SCHEMBL669943 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1062240-B1 | N-TERMINALLY MODIFIED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2010-04-28 | — | — | EP | claimed |
| US-6458924-B2 | POLYPEPTIDE DRUG; ANTIDIABETIC AGENT; Liraglutide | NOVO NORDISK A/S (DK) | 2002-10-01 | — | — | US | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |